SI2009000T1 - Selektivni serotoninski 2A/2C receptorski inverzni agonisti kot terapevtiki za nevrodegenerativne bolezni - Google Patents

Selektivni serotoninski 2A/2C receptorski inverzni agonisti kot terapevtiki za nevrodegenerativne bolezni

Info

Publication number: SI2009000T1
Authority: SI; Slovenia
Prior art keywords: receptor inverse; compound; neurodegenerative diseases; therapeutics; efficacy
Prior art date: 2003-01-16

Application number

SI200431728T

Other languages

English (en)

Inventor

M David Weiner

Robert E Davis

Mark R Brann

Norman Nash

Carl-Magnus A Andersson

Allan K Uldam

Original Assignee

Acadia Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-16

Filing date

2004-01-15

Publication date

2011-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2009000(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-15 Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc

2011-09-30 Publication of SI2009000T1 publication Critical patent/SI2009000T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SI200431728T 2003-01-16 2004-01-15 Selektivni serotoninski 2A/2C receptorski inverzni agonisti kot terapevtiki za nevrodegenerativne bolezni SI2009000T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44140603P	2003-01-16	2003-01-16
US47934603P	2003-06-17	2003-06-17
EP08015449A EP2009000B1 (en)	2003-01-16	2004-01-15	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Publications (1)

Publication Number	Publication Date
SI2009000T1 true SI2009000T1 (sl)	2011-09-30

Family

ID=32776052

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200431728T SI2009000T1 (sl)	2003-01-16	2004-01-15	Selektivni serotoninski 2A/2C receptorski inverzni agonisti kot terapevtiki za nevrodegenerativne bolezni
SI200430956T SI1587789T1 (sl)	2003-01-16	2004-01-15	Selektivni inverzni agonisti serotoninskega 2A/2Creceptorja kot terapevtiki za nevrodegenerativne bolezni

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200430956T SI1587789T1 (sl)	2003-01-16	2004-01-15	Selektivni inverzni agonisti serotoninskega 2A/2Creceptorja kot terapevtiki za nevrodegenerativne bolezni

Country Status (21)

Country	Link
US (17)	US7601740B2 (sl)
EP (2)	EP1587789B1 (sl)
JP (2)	JP5184777B2 (sl)
KR (1)	KR101095939B1 (sl)
CN (3)	CN1816524B (sl)
AT (2)	ATE407117T1 (sl)
AU (1)	AU2004206886B2 (sl)
BR (1)	BRPI0406591B8 (sl)
CA (1)	CA2512639C (sl)
CY (1)	CY1108642T1 (sl)
DE (1)	DE602004016288D1 (sl)
DK (2)	DK2009000T3 (sl)
ES (2)	ES2367135T3 (sl)
MX (1)	MXPA05007568A (sl)
NZ (1)	NZ541146A (sl)
PT (1)	PT1587789E (sl)
RU (2)	RU2332401C2 (sl)
SG (1)	SG170617A1 (sl)
SI (2)	SI2009000T1 (sl)
WO (1)	WO2004064738A2 (sl)
ZA (1)	ZA200505680B (sl)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ520240A (en) *	2000-03-06	2005-04-29	Acadia Pharm Inc	Azacyclic compounds for use in the treatment of serotonin related diseases
DE10066158B4 (de) *	2000-08-24	2007-08-09	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de)	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
ATE466014T1 (de)	2001-12-28	2010-05-15	Acadia Pharm Inc	Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
BR0312217A (pt) *	2002-06-24	2005-05-10	Acadia Pharm Inc	Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) *	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) *	2002-09-04	2009-10-30	Bristol Myers Squibb Co	Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2004064738A2 (en)	2003-01-16	2004-08-05	Acadia Pharmaceuticals Inc.	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
KR20050092123A (ko) *	2003-01-23	2005-09-20	아카디아 파마슈티칼스 인코포레이티드	Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도
US20040253274A1 (en) *	2003-06-11	2004-12-16	Allergan, Inc.	Use of a clostridial toxin to reduce appetite
NZ527142A (en) *	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
US7855195B2 (en) *	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) *	2003-12-02	2005-06-02	Erik Buntinx	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) *	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) *	2003-12-02	2005-09-15	Erik Buntinx	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) *	2003-12-02	2011-01-12	PharmaNeuroBoost N.V.	Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
ES2324713T3 (es)	2003-12-22	2009-08-13	Acadia Pharmaceuticals Inc.	Analogos de diaril(a,d)ciclohepteno amino-sustituidos como agonistas muscarinicos y metodos de tratamiento de trastornos neuropsiquiatricos.
US20050261278A1 (en) *	2004-05-21	2005-11-24	Weiner David M	Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) *	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
PL2289879T3 (pl) *	2004-09-27	2015-05-29	Acadia Pharm Inc	Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu
KR20060030175A (ko) *	2004-10-05	2006-04-10	경북대학교 산학협력단	무정위성 운동 치료용 약학조성물
PA8720601A1 (es) *	2006-03-24	2008-11-19	Wyeth Corp	Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
US20080051429A1 (en) *	2006-04-19	2008-02-28	Van Kammen Daniel	Use of 4-amino-piperidines for treating sleep disorders
CA2652300A1 (en) *	2006-05-15	2007-11-22	Acadia Pharmaceuticals Inc.	Pharmaceutical formulations of pimavanserin
US20080040819A1 (en) *	2006-08-14	2008-02-14	Wyeth	Methods of identifying agents for treatment of schizophrenia and related disorders
US20080254118A1 (en) *	2007-04-11	2008-10-16	Hans-Werner Wernersbach	Process for preparing pramipexole dihydrochloride tablets
KR101141185B1 (ko) *	2007-01-26	2012-07-12	오쓰까 세이야꾸 가부시키가이샤	치료의 제안된 효능 검출용 마커
ES2423485T3 (es) *	2007-03-19	2013-09-20	Acadia Pharmaceuticals Inc.	Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
US20080254117A1 (en) *	2007-04-10	2008-10-16	Noel Cotton	Process for preparing pramipexole dihydrochloride tablets
EP2150239A1 (en) *	2007-04-24	2010-02-10	Boehringer Ingelheim International GmbH	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2009003147A1 (en) *	2007-06-26	2008-12-31	Parkinson's Institute	Methods and compositions for the treatment of neurological disorders
WO2009039460A2 (en) *	2007-09-21	2009-03-26	Acadia Pharmaceuticals, Inc.	Co-administration of pimavanserin with other agents
US20090082342A1 (en) *	2007-09-21	2009-03-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9034911B2 (en)	2008-10-28	2015-05-19	Arena Pharmaceuticals, Inc.	Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
US20150080404A1 (en)	2012-04-14	2015-03-19	Intra-Cellular Therapies, Inc.	Novel compositions and methods
US9446037B2 (en)	2012-11-27	2016-09-20	Acadia Pharmaceuticals Inc.	Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR102692169B1 (ko)	2013-12-03	2024-08-05	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
TWI690512B (zh)	2014-03-07	2020-04-11	瑞士商赫爾辛保健股份有限公司	對位取代的不對稱脲及其醫療用途
CN104961671B (zh) *	2014-09-05	2018-01-02	苏州晶云药物科技有限公司	N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
KR20220071297A (ko) *	2015-01-28	2022-05-31	주식회사 제네리스코리아	신경정신계 장애의 치료를 위한 조성물 및 방법
US10343993B2 (en)	2015-03-02	2019-07-09	Pliva Hrvatska D.O.O.	Processes and intermediates for the preparation of Pimavanserin
EP3322415A4 (en) *	2015-07-15	2019-03-13	Axovant Sciences GmbH	DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
SI3325444T1 (sl)	2015-07-20	2021-11-30	Acadia Pharmaceuticals Inc.	Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
CZ2015601A3 (cs)	2015-09-02	2017-03-15	Zentiva, K.S.	Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CZ2015688A3 (cs)	2015-10-02	2017-04-12	Zentiva, K.S.	Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů
CN105523993A (zh) *	2015-12-28	2016-04-27	重庆两江药物研发中心有限公司	N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
GEP20217246B (en)	2016-03-22	2021-04-26	Healthcare Sa Helsinn	Benzenesulfonyl-asymmetric ureas and medical uses thereof
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
EP3436010B1 (en)	2016-03-29	2021-03-10	Acadia Pharmaceuticals Inc.	5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CN107343887A (zh) *	2016-05-06	2017-11-14	常州爱诺新睿医药技术有限公司	一种无定型半酒石酸匹莫范色林与药用辅料的固体分散体及其制备方法
CN106179449B (zh) *	2016-07-18	2018-11-13	南京工业大学	一种碳氮材料负载的钴催化剂及合成哌马色林中间体的方法
JP2019526611A (ja)	2016-09-13	2019-09-19	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	非タンパク質クロストリジウム毒素組成物
WO2018064465A1 (en)	2016-09-29	2018-04-05	The Regents Of The University Of California	Compounds for increasing neural plasticity
WO2018071233A1 (en)	2016-10-12	2018-04-19	Intra-Cellular Therapies, Inc.	Amorphous solid dispersions
EP3558311A1 (en)	2016-12-20	2019-10-30	Acadia Pharmaceuticals Inc.	Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
JP7132939B2 (ja)	2017-03-24	2022-09-07	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規組成物および方法
US11135211B2 (en)	2017-04-28	2021-10-05	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
CN110996947A (zh)	2017-05-25	2020-04-10	格莱泰施有限责任公司	N-甲基-d-天冬氨酸型谷氨酸受体拮抗剂反应性神经精神性疾病的联合治疗
CN110996948A (zh)	2017-06-12	2020-04-10	格莱泰施有限责任公司	用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
CN109111385B (zh) *	2017-06-23	2023-06-30	上海翰森生物医药科技有限公司	5-ht2a受体抑制剂及其制备方法和应用
EP4635568A3 (en)	2017-08-21	2025-12-03	ACADIA Pharmaceuticals Inc.	Compounds, salts thereof and methods for treatment of diseases
EP3672960A2 (en)	2017-08-21	2020-07-01	Acadia Pharmaceuticals Inc.	Compounds, salts thereof and their use for the treatment of diseases
EP3675827A1 (en)	2017-08-30	2020-07-08	Acadia Pharmaceuticals Inc.	Formulations of pimavanserin
CN109568278A (zh) *	2017-09-28	2019-04-05	北京万全德众医药生物技术有限公司	匹莫范色林片剂及其制备方法
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11357766B2 (en) *	2017-11-13	2022-06-14	Texas Tech University System	Compositions and methods for treating cancer
KR102036909B1 (ko) *	2017-11-28	2019-10-25	한국과학기술원	신규 디스토니아 치료용 약학적 조성물
MX2020009668A (es)	2018-03-16	2021-01-08	Intra Cellular Therapies Inc	Métodos novedosos.
IT201800003736A1 (it)	2018-03-19	2019-09-19	Lundbeck Pharmaceuticals Italy S P A	Processo per la produzione di Pimavanserin
US20190359985A1 (en) *	2018-05-22	2019-11-28	John Lawrence Mee	Adjustable method for sustainable human cognitive enhancement
CN108947891B (zh)	2018-07-26	2021-02-09	丽珠集团新北江制药股份有限公司	利用三光气安全制备匹莫范色林及其酒石酸盐的方法
US12144808B2 (en)	2018-08-29	2024-11-19	Intra-Cellular Therapies, Inc.	Compositions and methods
KR102906995B1 (ko)	2018-08-31	2025-12-31	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
US10695345B2 (en)	2018-08-31	2020-06-30	Intra-Cellular Therapies, Inc.	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
IT201800009690A1 (it)	2018-10-23	2020-04-23	Lundbeck Pharmaceuticals Italy Spa	Processo per la produzione di pimavanserina
MX2021010198A (es)	2019-02-27	2021-09-21	Univ California	Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
WO2020176599A1 (en)	2019-02-27	2020-09-03	The Regents Of The University Of California	Azepino-indoles and other heterocycles for treating brain disorders
WO2020212952A1 (en)	2019-04-17	2020-10-22	Compass Pathfinder Limited	Treatment of depression and other various disorders with psilocybin
EP3993798A4 (en)	2019-07-07	2023-04-26	Intra-Cellular Therapies, Inc.	NOVEL PROCESSES
WO2021016369A1 (en)	2019-07-22	2021-01-28	Acadia Pharmaceuticals Inc.	Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20220323429A1 (en) *	2019-08-15	2022-10-13	Acadia Pharmaceuticals Inc.	Pimavanserin for treating neurodegenerative diseases
KR102227268B1 (ko) *	2019-10-07	2021-03-12	한국과학기술원	디스토니아 치료 후보 약물의 신규 스크리닝 방법
CN115677723B (zh) *	2020-01-21	2024-06-04	瀚远医药有限公司	5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
WO2021147818A1 (zh) *	2020-01-21	2021-07-29	瀚远医药有限公司	5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) *	2020-01-21	2022-04-08	瀚远医药有限公司	5ht2a受体拮抗剂及其制备和应用
WO2021193790A1 (ja)	2020-03-26	2021-09-30	塩野義製薬株式会社	セロトニン受容体結合活性を有する芳香族複素環誘導体
WO2021206741A1 (en) *	2020-04-09	2021-10-14	Delahoussaye Kevin	Modulating neurotransmitter concentration
EP4186893A4 (en) *	2020-07-22	2025-02-05	Geneora Pharma (Shijiazhuang) Co., Ltd.	5-ht2a receptor inhibitor or inverse agonist, preparation method therefor, and application thereof
US11071739B1 (en)	2020-09-29	2021-07-27	Genus Lifesciences Inc.	Oral liquid compositions including chlorpromazine
JP2023549174A (ja) *	2020-11-04	2023-11-22	グリアセルテック・インコーポレイテッド	クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物
CN113292484B (zh) *	2021-06-04	2022-11-15	沈阳药科大学	3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
AU2022416279A1 (en)	2021-12-15	2024-07-25	Delix Therapeutics, Inc.	Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods
AU2023319750A1 (en)	2022-08-03	2025-02-13	Luye Innomind Pharma Shijiazhuang Co., Ltd.	5-ht2a receptor inverse agonist, and preparation method therefor and use thereof
JP7406285B1 (ja)	2023-03-09	2023-12-27	国立大学法人島根大学	ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物
WO2025162237A1 (zh) *	2024-02-02	2025-08-07	绿叶嘉奥制药石家庄有限公司	一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA684843A (en)		1964-04-21	P. Roberts Cecil	Cap aligning mechanism
US165225A (en) *		1875-07-06		Improvement in hubs
BE794333A (fr)	1972-01-20	1973-07-19	Wyeth John & Brother Ltd	Composes heterocycliques azotes therapeutiques
GB1507462A (en) *	1974-03-21	1978-04-12	Gallardo Antonio Sa	N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) *	1974-07-04	1976-09-28	Sandoz Ltd.	Treatment of dyskinesias
JPS5152176A (sl)	1974-10-12	1976-05-08	Yoshitomi Pharmaceutical
JPS528517A (en)	1975-07-09	1977-01-22	Toyo Autom Kk	Fluid line automatic closing system at an earthquake
GB1586468A (en) *	1976-10-29	1981-03-18	Anphar Sa	Piperidine derivatives
CA1140119A (en)	1978-04-03	1983-01-25	Joseph Torremans	N-heterocyclyl-4-piperidinamines
US4255432A (en) *	1979-09-06	1981-03-10	Syntex (U.S.A.) Inc.	8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en)	1981-03-23	1982-06-01	Syntex (U.S.A.) Inc.	9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en) *	1981-10-19	1982-10-12	Syntex (U.S.A.) Inc.	9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) *	1981-10-19	1982-10-12	Syntex (U.S.A.) Inc.	9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
GB8527052D0 (en) *	1985-11-02	1985-12-04	Beecham Group Plc	Compounds
GB8621892D0 (en)	1986-09-11	1986-10-15	Lundbeck & Co As H	Organic compound
FR2642069B1 (fr) *	1989-01-20	1991-04-12	Rhone Poulenc Sante	Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) *	1990-05-18	1993-05-25	Adir Et Compagnie	Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) *	1990-10-03	1993-06-01	American Home Products Corporation	N-substituted aminoquinolines as analgesic agents
IT1252227B (it)	1991-12-17	1995-06-05	Ciba Geigy Spa	Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
JPH05208517A (ja)	1992-01-31	1993-08-20	Nec Corp	印字制御回路
US5595872A (en) *	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) *	1993-05-21	1994-11-22	Noriyoshi Sueda	Urea derivatives and their use as acat inhibitors
AU6971794A (en)	1993-05-26	1994-12-20	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
US5707798A (en)	1993-07-13	1998-01-13	Novo Nordisk A/S	Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) *	1994-02-10	1995-08-17	Merck Patent Gmbh	4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) *	1995-05-02	1998-08-18	Schering Corporation	Piperazino derivatives as neurokinn antagonists
BR9610277A (pt)	1995-08-31	1999-07-06	Schering Corp	Derivados de piperazino como antagonistas de neurowuinina
CA2233204A1 (en)	1995-09-29	1997-04-03	Joseph A. Jakubowski	Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
EP0871440B1 (en) *	1995-12-07	2006-03-22	Daniel C. Javitt	Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
AU715202B2 (en)	1996-04-03	2000-01-20	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
ATE269312T1 (de)	1996-04-17	2004-07-15	Bristol Myers Squibb Pharma Co	N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
US5869488A (en) *	1996-05-01	1999-02-09	Schering Corporation	Piperazino derivatives as neurokinin antagonists
WO1998007431A1 (en) *	1996-08-22	1998-02-26	New York University	Cholinesterase inhibitors for treatment of parkinson's disease
US5877173A (en) *	1996-08-28	1999-03-02	Washington University	Preventing neuronal degeneration in Alzheimer's disease
BR9712023A (pt)	1996-09-10	1999-08-31	Thomae Gmbh Dr K	Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
DE19643331A1 (de)	1996-10-21	1998-04-23	Thomae Gmbh Dr K	1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9604786D0 (sv) *	1996-12-20	1996-12-20	Astra Pharma Inc	New compounds
US6057338A (en)	1997-04-04	2000-05-02	Merck & Co., Inc.	Somatostatin agonists
HUP0001285A3 (en)	1997-05-08	2000-10-30	Smithkline Beecham Corp Philap	Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
GB9718833D0 (en) *	1997-09-04	1997-11-12	Merck Sharp & Dohme	Therapeutic agents
MXPA00010060A (es) *	1998-04-14	2004-04-23	Arena Pharm Inc	Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
US6140509A (en) *	1998-06-26	2000-10-31	Arena Pharmaceuticals, Inc.	Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) *	1998-07-24	1998-09-23	Merck Sharp & Dohme	Therapeutic agents
US6358698B1 (en) *	1998-10-07	2002-03-19	Acadia Pharmacueticals Inc.	Methods of identifying inverse agonists of the serotonin 2A receptor
US6559146B1 (en)	1998-10-16	2003-05-06	Suntory Limited	Aminophenoxyacetic acid derivatives as neuroprotectants
US6150393A (en) *	1998-12-18	2000-11-21	Arena Pharmaceuticals, Inc.	Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (en) *	1998-12-23	2000-06-28	Pfizer Inc.	Aminoazacycloalkanes as CCR5 modulators
US6725038B1 (en)	1999-01-26	2004-04-20	Nokia Corporation	Method and apparatus for speeding up AAL2 connection setup during handover in advanced cellular networks
EP1178800A4 (en)	1999-03-24	2002-07-31	Univ California	Method of treating neurodegenerative disorders using aspartyl protease inhibitors
US6399619B1 (en)	1999-04-06	2002-06-04	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
HUP0201033A3 (en)	1999-05-17	2003-03-28	Novo Nordisk As	Glucagon antagonists/inverse agonists, process for their preparation and their use
US20050148018A1 (en) *	1999-10-07	2005-07-07	David Weiner	Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr)	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) *	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6834122B2 (en)	2000-01-22	2004-12-21	Kairos Scientific, Inc.	Visualization and processing of multidimensional data using prefiltering and sorting criteria
NZ520240A (en) *	2000-03-06	2005-04-29	Acadia Pharm Inc	Azacyclic compounds for use in the treatment of serotonin related diseases
GB0011838D0 (en) *	2000-05-17	2000-07-05	Astrazeneca Ab	Chemical compounds
DE60141752D1 (de) *	2000-06-30	2010-05-20	Innogenetics Nv	Differentielle diagnose von neurologischen krankheiten
BR0113989A (pt)	2000-09-25	2004-01-27	Actelion Pharmaceuticals Ltd	Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
US20020156068A1 (en) *	2001-03-22	2002-10-24	Behan Dominic P.	Anti-psychosis combination
GB0108099D0 (en)	2001-03-30	2001-05-23	Hoffmann La Roche	Aminopiperidine derivatives
ATE466014T1 (de)	2001-12-28	2010-05-15	Acadia Pharm Inc	Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
WO2003062206A2 (en)	2002-01-23	2003-07-31	Arena Pharmaceuticals, Inc.	Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UY27668A1 (es)	2002-02-20	2003-10-31	Pfizer Prod Inc	Composición de ziprasidona y controles sintéticos
GB0208279D0 (en)	2002-04-10	2002-05-22	Glaxo Group Ltd	Novel compounds
US7253186B2 (en) *	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
BR0312217A (pt)	2002-06-24	2005-05-10	Acadia Pharm Inc	Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
US7538222B2 (en) *	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
AU2003284899A1 (en)	2002-10-29	2004-05-25	Miicro, Inc.	Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
WO2004064738A2 (en) *	2003-01-16	2004-08-05	Acadia Pharmaceuticals Inc.	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
KR20050092123A (ko)	2003-01-23	2005-09-20	아카디아 파마슈티칼스 인코포레이티드	Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도
EP2272514A1 (en)	2003-12-02	2011-01-12	PharmaNeuroBoost N.V.	Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
ES2324713T3 (es)	2003-12-22	2009-08-13	Acadia Pharmaceuticals Inc.	Analogos de diaril(a,d)ciclohepteno amino-sustituidos como agonistas muscarinicos y metodos de tratamiento de trastornos neuropsiquiatricos.
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en)	2004-05-21	2005-11-24	Weiner David M	Selective serotonin receptor inverse agonists as therapeutics for disease
PL2289879T3 (pl)	2004-09-27	2015-05-29	Acadia Pharm Inc	Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP5208517B2 (ja)	2005-01-10	2013-06-12	タヘリラドュカエルエルシー	血管移植物およびその製造方法
US7803951B2 (en)	2005-03-30	2010-09-28	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8572080B2 (en)	2010-06-04	2013-10-29	Salesforce.Com, Inc.	Methods and systems for analyzing a network feed in a multi-tenant database system environment
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
US9446037B2 (en) *	2012-11-27	2016-09-20	Acadia Pharmaceuticals Inc.	Methods for the treatment of parkinson's disease psychosis using pimavanserin
WO2017165635A1 (en) *	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) *	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
EP3675827A1 (en) *	2017-08-30	2020-07-08	Acadia Pharmaceuticals Inc.	Formulations of pimavanserin

2004
- 2004-01-15 WO PCT/US2004/001234 patent/WO2004064738A2/en not_active Ceased
- 2004-01-15 JP JP2006501009A patent/JP5184777B2/ja not_active Expired - Lifetime
- 2004-01-15 AU AU2004206886A patent/AU2004206886B2/en not_active Expired
- 2004-01-15 PT PT04702584T patent/PT1587789E/pt unknown
- 2004-01-15 MX MXPA05007568A patent/MXPA05007568A/es active IP Right Grant
- 2004-01-15 RU RU2005125918/04A patent/RU2332401C2/ru active
- 2004-01-15 DK DK08015449.5T patent/DK2009000T3/da active
- 2004-01-15 KR KR1020057013195A patent/KR101095939B1/ko not_active Expired - Lifetime
- 2004-01-15 CN CN2004800044790A patent/CN1816524B/zh not_active Expired - Lifetime
- 2004-01-15 EP EP04702584A patent/EP1587789B1/en not_active Expired - Lifetime
- 2004-01-15 DK DK04702584T patent/DK1587789T3/da active
- 2004-01-15 SI SI200431728T patent/SI2009000T1/sl unknown
- 2004-01-15 CN CN200910225582.2A patent/CN101780080B/zh not_active Expired - Lifetime
- 2004-01-15 CA CA2512639A patent/CA2512639C/en not_active Expired - Lifetime
- 2004-01-15 AT AT04702584T patent/ATE407117T1/de active
- 2004-01-15 CN CN2010105460287A patent/CN102028949A/zh active Pending
- 2004-01-15 ES ES08015449T patent/ES2367135T3/es not_active Expired - Lifetime
- 2004-01-15 US US10/759,561 patent/US7601740B2/en active Active
- 2004-01-15 DE DE602004016288T patent/DE602004016288D1/de not_active Expired - Lifetime
- 2004-01-15 ES ES04702584T patent/ES2314362T3/es not_active Expired - Lifetime
- 2004-01-15 NZ NZ541146A patent/NZ541146A/en not_active IP Right Cessation
- 2004-01-15 BR BRPI0406591A patent/BRPI0406591B8/pt not_active IP Right Cessation
- 2004-01-15 AT AT08015449T patent/ATE512136T1/de not_active IP Right Cessation
- 2004-01-15 SG SG200705308-5A patent/SG170617A1/en unknown
- 2004-01-15 SI SI200430956T patent/SI1587789T1/sl unknown
- 2004-01-15 EP EP08015449A patent/EP2009000B1/en not_active Expired - Lifetime
2005
- 2005-07-14 ZA ZA200505680A patent/ZA200505680B/en unknown
2006
- 2006-05-03 US US11/416,527 patent/US7732462B2/en active Active
- 2006-05-03 US US11/416,855 patent/US7659285B2/en active Active
- 2006-05-03 US US11/416,594 patent/US7713995B2/en not_active Expired - Lifetime
2008
- 2008-04-16 RU RU2008115009/04A patent/RU2465267C2/ru active
- 2008-12-03 CY CY20081101402T patent/CY1108642T1/el unknown
2010
- 2010-03-10 JP JP2010053450A patent/JP2010174026A/ja active Pending
- 2010-04-13 US US12/759,664 patent/US8008323B2/en not_active Expired - Lifetime
- 2010-04-13 US US12/759,662 patent/US7994193B2/en not_active Expired - Lifetime
2011
- 2011-06-27 US US13/169,893 patent/US8227487B2/en not_active Expired - Fee Related
2012
- 2012-06-29 US US13/539,011 patent/US8377959B2/en not_active Expired - Fee Related
2013
- 2013-01-25 US US13/750,778 patent/US8618130B2/en not_active Expired - Fee Related
- 2013-11-21 US US14/086,838 patent/US8921393B2/en not_active Expired - Lifetime
2014
- 2014-11-10 US US14/537,793 patent/US9211289B2/en not_active Expired - Lifetime
2015
- 2015-11-06 US US14/935,246 patent/US9566271B2/en not_active Expired - Fee Related
2017
- 2017-01-03 US US15/397,582 patent/US10028944B2/en not_active Expired - Lifetime
2018
- 2018-06-26 US US16/019,485 patent/US10525046B2/en not_active Expired - Lifetime
2019
- 2019-11-18 US US16/687,467 patent/US20200323836A1/en not_active Abandoned
2021
- 2021-01-29 US US17/162,476 patent/US20240091212A1/en not_active Abandoned
- 2021-09-14 US US17/474,816 patent/US20220241265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2010174026A (ja)	2010-08-12
CN101780080A (zh)	2010-07-21
BRPI0406591B1 (pt)	2018-12-18
RU2005125918A (ru)	2006-02-10
US20110257229A1 (en)	2011-10-20
DE602004016288D1 (de)	2008-10-16
ES2367135T3 (es)	2011-10-28
US20060199842A1 (en)	2006-09-07
CN101780080B (zh)	2014-06-04
US20240091212A1 (en)	2024-03-21
AU2004206886A1 (en)	2004-08-05
MXPA05007568A (es)	2005-09-21
HK1126776A1 (en)	2009-09-11
US8377959B2 (en)	2013-02-19
US20170209424A1 (en)	2017-07-27
US7713995B2 (en)	2010-05-11
US20160250200A1 (en)	2016-09-01
AU2004206886B2 (en)	2010-09-02
DK2009000T3 (da)	2011-09-05
US9566271B2 (en)	2017-02-14
US10028944B2 (en)	2018-07-24
ES2314362T3 (es)	2009-03-16
HK1083759A1 (en)	2006-07-14
EP2009000B1 (en)	2011-06-08
SI1587789T1 (sl)	2009-02-28
CA2512639A1 (en)	2004-08-05
KR20050094857A (ko)	2005-09-28
US8921393B2 (en)	2014-12-30
US20190030015A1 (en)	2019-01-31
US20060264466A1 (en)	2006-11-23
EP1587789B1 (en)	2008-09-03
US20040213816A1 (en)	2004-10-28
EP2009000A1 (en)	2008-12-31
US20100227886A1 (en)	2010-09-09
US9211289B2 (en)	2015-12-15
US8008323B2 (en)	2011-08-30
WO2004064738A2 (en)	2004-08-05
ZA200505680B (en)	2006-04-26
US20100227885A1 (en)	2010-09-09
US8618130B2 (en)	2013-12-31
RU2008115009A (ru)	2009-10-27
US7994193B2 (en)	2011-08-09
US20200323836A1 (en)	2020-10-15
EP1587789A2 (en)	2005-10-26
CN1816524B (zh)	2012-06-27
JP2006516284A (ja)	2006-06-29
US10525046B2 (en)	2020-01-07
SG170617A1 (en)	2011-05-30
CN1816524A (zh)	2006-08-09
US7659285B2 (en)	2010-02-09
RU2332401C2 (ru)	2008-08-27
JP5184777B2 (ja)	2013-04-17
KR101095939B1 (ko)	2011-12-19
US20120277221A1 (en)	2012-11-01
NZ541146A (en)	2009-04-30
DK1587789T3 (da)	2009-01-05
US20060264465A1 (en)	2006-11-23
CY1108642T1 (el)	2014-04-09
CA2512639C (en)	2012-10-30
ATE512136T1 (de)	2011-06-15
US20150202194A1 (en)	2015-07-23
US8227487B2 (en)	2012-07-24
PT1587789E (pt)	2008-12-16
BRPI0406591B8 (pt)	2021-05-25
US20220241265A1 (en)	2022-08-04
US7601740B2 (en)	2009-10-13
CN102028949A (zh)	2011-04-27
ATE407117T1 (de)	2008-09-15
WO2004064738A3 (en)	2004-11-25
US7732462B2 (en)	2010-06-08
BRPI0406591A (pt)	2005-12-20
US20140140982A1 (en)	2014-05-22
RU2465267C2 (ru)	2012-10-27
US20130137727A1 (en)	2013-05-30

Publication	Publication Date	Title
PT1587789E (pt)	2008-12-16	Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
IL249715B (en)	2018-11-29	N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent
EP1861161A4 (en)	2012-05-16	APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
EP1583750A4 (en)	2010-06-23	MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
CL2011000044A1 (es)	2011-06-17	Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
IL198519A (en)	2014-07-31	7 of the 1, 2, 3, 11- tetrahydro-5, 11-diazo-benzo [a] Trindein-4, 6- deion and its derivatives for use as radiation susceptibility factors for cancer treatment
EP1656359A4 (en)	2010-07-07	MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
TWI366469B (en)	2012-06-21	Emulsified skin agent for external use
IL182047A0 (en)	2007-07-24	Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
EP2035412A4 (en)	2011-02-16	MUSCARINIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
BRPI0921097A2 (pt)	2016-09-06	composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento.
IL195431A0 (en)	2009-08-03	Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
AU2003304410A8 (en)	2005-03-07	Agents and methods for treatment of disease by oligosaccharide targeting agents
IL177787A0 (en)	2006-12-31	1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
AU2003263972A8 (en)	2004-02-25	Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
EP1921926A4 (en)	2010-02-24	FEED FORMULATION FOR WATER ANIMALS WITH INTEGRATED TARGETED DISTRIBUTION OF BIOLOGICAL ACTIVE SUBSTANCES
EP1951709A4 (en)	2010-11-10	IMIDAZOLIDINONE COMPOUNDS AS A BETA SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
PL1863435T3 (pl)	2017-05-31	Zwiększone dostarczanie środków korzystnych dla skóry
SE0302794D0 (sv)	2003-10-24	Novel microparticles for ultrasound contrast imaging and drug delivery
EP1867337A4 (en)	2012-11-21	MEDICAL COMPOSITION FOR THE TREATMENT / PREVENTION OF MOTOR ORGANIC DISEASES
ZA200707487B (en)	2008-12-31	Enhanced delivery of skin benefit agents
DE50300597D1 (de)	2005-07-07	Fanghakeneinrichtung für eine Fronthaube eines Kraftfahrzeugs
UA11825S (uk)	2006-03-15	Куртка жіноча хутрова «моніка». модель 20-мв.
UA13322S (uk)	2006-12-15	Пальто жіноче хутрове комбіноване «вишневий йогурт». модель мв
ITMI20040411A1 (it)	2004-06-04	Macchina perfezionata per l'inscatolamento di pesce carne e simili